Safety of SGLT2 Inhibitors in Three Chronic Diseases
International Heart Journal · 2023
DOI: 10.1536/ihj.22-441 ↗Kurz gefasst
Metaanalyse in der Zeitschrift International Heart Journal, 2023. Verfasst von Shiyao Ge und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Statistics, School of Public Health, Hebei Medical University. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Diabetic Ketoacidosis, Hypoglycemia. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology and Statistics, School of Public Health, Hebei Medical University.
- Hebei Province Key Laboratory of Environment and Human Health.
Zitieren
APA
Ge, S., Liu, R., Mao, Y., Geng, C., Wang, H., Song, K., & Tian, Q. B. (2023). Safety of SGLT2 Inhibitors in Three Chronic Diseases. International Heart Journal. https://doi.org/10.1536/ihj.22-441
Vancouver
Ge S, Liu R, Mao Y, Geng C, Wang H, Song K, et al. Safety of SGLT2 Inhibitors in Three Chronic Diseases. International Heart Journal. 2023. doi:10.1536/ihj.22-441
BibTeX
@article{Ge2023,
author = {Ge, Shiyao and Liu, Ruobin and Mao, Yucheng and Geng, Chang and Wang, Hongfei and Song, Kai and Tian, Qing-Bao},
title = {Safety of SGLT2 Inhibitors in Three Chronic Diseases},
journal = {International Heart Journal},
year = {2023},
doi = {10.1536/ihj.22-441}
}
EUVIMED